No Data
Should Weakness in Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jiangzhong Pharmaceutical (600750.SH) plans to distribute 0.7 yuan per share in 2023, with ex-rights and ex-dividends on June 13.
Jiangzhong Pharmaceutical (600750.SH) announced its plan to distribute a cash dividend of 0.7 yuan per share for the 2023 fiscal year.
Zhitong A Share Sale Restriction and Release List | May 30
According to the Zhitong Finance App, the ban on restricted shares of 6 listed companies was lifted on May 30, with a total market value of about 1,908 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Jiangzhong Pharmaceutical's 600,750 shares incentive to sell and circulate 148,000, Midea Group 000333, share incentives, limited sale and circulation, 50436 million, Yi Hualu 300212, corporate placement and listing of 574.591 million Dongxing Medical 301,290, extended sales restrictions and regular circulation 725,000 Xinruida 002983 shares incentive limited circulation 812,000 Pryder 30
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit of 267 million yuan in the first quarter increased 9.99% year-on-year
Gelonghui, April 29丨China Resources Pharmaceutical (03320.HK) announced that Jiangzhong Pharmaceutical (600750.SH) achieved operating income of 1,227 billion yuan in the first quarter of 2024, down 8.74% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) was 267 million yuan, up 9.99% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) after deducting non-recurring profit and loss was 264 million yuan, up 16.64% year on year.
Jiangzhong Pharmaceutical (600750.SH) reported first-quarter results with net profit of 267 million yuan, up 9.99% year on year
According to the Zhitong Finance App, Jiangzhong Pharmaceutical (600750.SH) released its report for the first quarter of 2024, achieving revenue of 1,227 billion yuan, a year-on-year decrease of 8.74%. Net profit attributable to shareholders of listed companies was 267 million yuan, an increase of 9.99% over the previous year. Achieved net profit of 264 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 16.64% over the previous year.
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit in 2023 increased by 708 million yuan year on year, up 18.4% year on year
Gelonghui, March 25, 丨 China Resources Pharmaceutical (03320.HK) issued an announcement. Jiangzhong Pharmaceutical (600750.SH) announced its 2023 annual report, with operating revenue of RMB 4.39 billion, up 13.00% year on year; net profit attributable to Jiangzhong Pharmaceutical shareholders of RMB 708 million, up 18.4% year on year; net profit attributable to shareholders of Jiangzhong Pharmaceutical (after deducting non-recurring income or loss) of 704 million yuan, an increase of 38.97% year on year; basic earnings per share were 1.12 yuan. A cash dividend of 7 yuan is distributed for every 10 shares.
No Data
